Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasms × enasidenib × Clear all

Phase

Status

Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 9 Myelodysplastic Syndromes 2 Leukemia, Myelomonocytic, Chronic 2 Sinonasal undifferentiated carcinoma 1 Neoplasms 1 Myeloproliferative Disorders 1 Lymphoma, T-Cell 1 Leukemia, Biphenotypic, Acute 1 Esthesioneuroblastoma, Olfactory 1 Chondrosarcoma 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

pembrolizumab 31 Blood Specimen Collection 29 Bevacizumab 18 Standard of Care 16 Radiotherapy 15 Carboplatin 14 Surveys and Questionnaires 13 Paclitaxel 13 Nivolumab 13 Exercise 13 Cisplatin 11 atezolizumab 10 Drug Therapy 10 Docetaxel 10 Dexamethasone 10 Cyclophosphamide 9 Pemetrexed 8 Fluorouracil 8 olaparib 7 Trastuzumab 7 Temozolomide 7 Leucovorin 7 Irinotecan 7 Interviews as Topic 7 Cetuximab 7 pertuzumab 6 Radiosurgery 6 Panitumumab 6 Oxaliplatin 6 Observation 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡